Chengdu Kanghua Biological Products Valuation

Is 300841 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300841 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300841 (CN¥57.5) is trading below our estimate of fair value (CN¥90.28)

Significantly Below Fair Value: 300841 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300841?

Key metric: As 300841 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 300841. This is calculated by dividing 300841's market cap by their current earnings.
What is 300841's PE Ratio?
PE Ratio	13.7x
Earnings	CN¥546.18m
Market Cap	CN¥7.47b

300841 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.2x
Enterprise Value/EBITDA	9.4x
PEG Ratio	0.8x

Price to Earnings Ratio vs Peers

How does 300841's PE Ratio compare to its peers?

The above table shows the PE ratio for 300841 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	30.8x
002880 Shenzhen Weiguang Biological Products	26.6x	13.8%	CN¥6.6b
300406 Beijing Strong BiotechnologiesInc	16.6x	23.2%	CN¥8.7b
300685 Amoy Diagnostics	33x	19.6%	CN¥10.2b
600201 Jinyu Bio-technology	46.9x	47.1%	CN¥7.6b
300841 Chengdu Kanghua Biological Products	13.7x	18.0%	CN¥7.5b

Price-To-Earnings vs Peers: 300841 is good value based on its Price-To-Earnings Ratio (13.7x) compared to the peer average (30.3x).

Price to Earnings Ratio vs Industry

How does 300841's PE Ratio compare vs other companies in the CN Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 300841 is good value based on its Price-To-Earnings Ratio (13.7x) compared to the CN Biotechs industry average (36.4x).

Price to Earnings Ratio vs Fair Ratio

What is 300841's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300841 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	13.7x
Fair PE Ratio	24.7x

Price-To-Earnings vs Fair Ratio: 300841 is good value based on its Price-To-Earnings Ratio (13.7x) compared to the estimated Fair Price-To-Earnings Ratio (24.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 300841 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	CN¥57.50	CN¥75.18 +30.7%	4.2%	CN¥78.35	CN¥72.00	n/a	2
Nov ’25	CN¥58.67	CN¥75.18 +28.1%	4.2%	CN¥78.35	CN¥72.00	n/a	2
Oct ’25	CN¥65.83	CN¥75.18 +14.2%	4.2%	CN¥78.35	CN¥72.00	n/a	2
Sep ’25	CN¥51.97	CN¥75.18 +44.7%	4.2%	CN¥78.35	CN¥72.00	n/a	2
Aug ’25	CN¥52.42	CN¥81.68 +55.8%	4.1%	CN¥85.00	CN¥78.35	n/a	2
Jul ’25	CN¥51.68	CN¥81.68 +58.0%	4.1%	CN¥85.00	CN¥78.35	n/a	2
Jun ’25	CN¥57.90	CN¥81.68 +41.1%	4.1%	CN¥85.00	CN¥78.35	n/a	2
May ’25	CN¥62.82	CN¥102.01 +62.4%	16.7%	CN¥119.02	CN¥85.00	n/a	2
Apr ’25	CN¥62.38	CN¥96.33 +54.4%	16.9%	CN¥119.02	CN¥81.97	n/a	3
Mar ’25	CN¥62.97	CN¥84.99 +35.0%	3.5%	CN¥88.00	CN¥81.97	n/a	2
Feb ’25	CN¥55.45	CN¥84.99 +53.3%	3.5%	CN¥88.00	CN¥81.97	n/a	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥47.5b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥31.84

-3.9%

14.4%

Dong-E-E-JiaoLtd

CN¥37.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.44

-2.0%

18.4%

China Resources Double-Crane PharmaceuticalLtd

CN¥22.3b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥21.72

-1.2%

18.8%